Deere & Company’s TG Therapeutics TGTX Stock Holding History

Deere & Company’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-33,089	Closed	-$524K	–	1059
2014 Q4	$524K	Buy	+33,089	New	+$431K	0.03%	586

Other funds holding TGTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Deere & Company's TGTX Position: Q1 2015 in Review

Deere & Company sold out of TG Therapeutics (TGTX) in Q1 2015, closing a stake of 33,089 shares — an estimated $524K sold.

Deere & Company first reported a position in TGTX in Q4 2014 and held it in 1 quarter. The position peaked at $524K in Q4 2014. 79 funds tracked by Wall St. Rank hold TGTX as of Q1 2015.

Deere & Company reported no remaining TG Therapeutics position as of Q1 2015 after selling out during the quarter.
Deere & Company sold 33,089 TG Therapeutics shares in Q1 2015, an estimated $524K.
Deere & Company first reported a position in TG Therapeutics in Q4 2014 and held it in 1 quarter.
Deere & Company's TG Therapeutics position peaked at $524K in Q4 2014.
79 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2015.

Based on Deere & Company's 13F filing for Q1 2015, filed 13 May 2015.